Why Draw an Antiphospholipid Antibody Panel?
Order an antiphospholipid antibody panel to diagnose antiphospholipid syndrome (APS) in patients with unexplained thrombosis (arterial or venous), recurrent pregnancy loss, or other pregnancy complications, as APS diagnosis is entirely dependent on accurate laboratory detection of these antibodies. 1
Clinical Indications for Testing
The antiphospholipid antibody panel is essential because clinical features of APS are not specific for the disease—diagnosis relies on laboratory confirmation 1. You should order this panel in the following scenarios:
Thrombotic Events
- Unexplained venous thromboembolism (deep venous thrombosis, pulmonary embolism)
- Arterial thrombosis (stroke, myocardial infarction, peripheral arterial occlusion), particularly in younger patients without traditional risk factors
- Cerebrovascular or retinal vessel thrombosis
- Recurrent thrombosis despite anticoagulation 2
Pregnancy Complications
- Recurrent early pregnancy loss (≥3 consecutive miscarriages before 10 weeks)
- Unexplained fetal death after 10 weeks gestation
- Severe preeclampsia or placental insufficiency requiring delivery before 34 weeks
- Thrombotic microangiopathy in pregnancy or postpartum 3
Other Clinical Scenarios
- Patients with systemic lupus erythematosus or other autoimmune diseases
- Unexplained thrombocytopenia
- Livedo reticularis with thrombosis
- Catastrophic APS presentation 1, 4
What the Panel Should Include
The complete antiphospholipid antibody panel must include three core tests to optimize diagnostic accuracy 1:
- Lupus anticoagulant (LA) - functional clotting assay using both dilute Russell's viper venom time (dRVVT) and LA-sensitive activated partial thromboplastin time (APTT) 1
- Anticardiolipin antibodies (aCL) - IgG and IgM isotypes by ELISA
- Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG and IgM isotypes by ELISA
Critical Testing Principles
Never rely on a single test. Omitting either the APTT or dRVVT increases the risk of underdiagnosis in up to 55% of triple-positive patients and 31% of APS patients 1. The combination of all three antibody types is mandatory because:
- LA positivity is the strongest predictor of thrombotic risk and identifies high-risk triple-positive patients 1
- Triple positivity (LA + aCL + aβ2GPI) carries the highest risk for thrombosis and pregnancy complications 5, 6
- Single positivity has lower thrombotic risk than double or triple positivity, informing management decisions 1
Risk Stratification Based on Results
The antibody profile directly impacts clinical risk and management:
- Triple positive: Highest risk (OR 23.2 for clinical events) 6
- Double positive: Intermediate risk (OR 7.3) 6
- Single positive LA: Lower but significant risk (OR 3.11) 6
- Isolated aCL or aβ2GPI: Lowest risk among positive results 6
Important Caveats
Test interpretation requires confirmation. A single positive test is insufficient—antibodies must be persistently positive on repeat testing at least 12 weeks apart to meet diagnostic criteria 1. This distinguishes true APS from transient antibody positivity seen with infections or other conditions 4.
Timing matters. The aPTT is unreliable for screening (prolonged in only 40-50% of patients with lupus anticoagulant), so definitive tests must be ordered directly when APS is suspected 2. Testing during vitamin K antagonist therapy can produce false negatives for LA 1.
Consider noncriteria antibodies in seronegative cases. Patients with clinical APS features but negative standard testing may benefit from measurement of antiphosphatidylserine-prothrombin (aPS/PT) antibodies or IgA isotypes, though these are not part of classification criteria 7.
The panel is not just diagnostic—it stratifies risk, guides anticoagulation intensity and duration, and informs pregnancy management decisions, making it indispensable when APS is clinically suspected 1, 3.